In September 2025, a federal press briefing put two medications at the center of the national autism conversation: acetaminophen, the active ingredient in Tylenol, which officials linked to autism when used during pregnancy, and leucovorin, a prescription form of folinic acid, which officials described as a promising treatment for speech-related deficits in some children with autism. A year later, families still bring both topics to us every week, often after seeing confident claims on social media or in group chats.
This article is not about politics. It is a plain-language summary of what the FDA actually did, what peer-reviewed research and the major pediatric organizations say as of September 2026, and how to turn a stressful headline into a productive conversation with your child's doctor.
One thing before we start: nothing in this article is medical advice. Decisions about any medication, for your child or during pregnancy, belong in a conversation with your pediatrician or obstetrician, not in a blog post and not in a press conference.
What was announced, and what the FDA actually did
The September 22, 2025 briefing announced three things: an FDA label pathway for leucovorin connected to cerebral folate deficiency, a notice to physicians about acetaminophen use in pregnancy, and new federal funding for autism research. It is worth noting that the government's own materials stated that leucovorin is not a cure for autism and may only lead to improvements in speech-related deficits for a subset of children.
The FDA action that followed was narrower than the headlines suggested. The label recognition is tied to cerebral folate deficiency, a rare condition in which folate does not reach the brain properly and which can involve autism-like symptoms. It is not an approval of leucovorin as a treatment for autism in general. That distinction is the single most important fact in this entire topic, and it is the one most often lost in the retelling.
What the research shows about leucovorin
A small number of small studies have suggested that leucovorin may improve some symptoms, particularly language, in some children with autism. Those findings are real, and they are also preliminary: large randomized controlled trials, the kind of evidence that changes clinical guidelines, have not been completed. Federal confirmatory trials were announced as part of the same initiative and are underway.
The American Academy of Pediatrics addressed this directly in its Interim Guidance on the Use of Leucovorin in Autistic Pediatric Patients, which does not recommend routine use of leucovorin for autistic children. The Society for Developmental and Behavioral Pediatrics has published statements for both clinicians and families, including a Spanish-language version, and both organizations point families back to individualized conversations with their own clinicians.
Prescriptions surged anyway. An analysis published in the New England Journal of Medicine found that filled leucovorin prescriptions for children rose 46 percent in the week of the briefing, and other peer-reviewed analyses documented similar spikes in the months that followed. A prescription surge reflects publicity, not new evidence. If your child's clinician recommends leucovorin after an individualized evaluation, that is a clinical decision you can discuss and understand. Starting it because of a headline is not.
What the research shows about acetaminophen in pregnancy
Some observational studies over the years have reported an association between acetaminophen use in pregnancy and autism. The difficulty is that associations of this kind can reflect the reasons a medication was taken, or shared family factors, rather than the medication itself. The strongest study design available for this question compares siblings within the same families, and the largest sibling-comparison study to date, published in JAMA in 2024 and covering roughly 2.4 million children in Sweden, found no association between prenatal acetaminophen exposure and autism once those family factors were accounted for.
The major medical organizations have not changed their position: acetaminophen remains the recommended first-line option for treating fever and pain during pregnancy when medication is needed, used at the lowest effective dose for the shortest necessary time. That guidance exists for a reason. Untreated high fever during pregnancy carries documented risks of its own, which is why clinicians became concerned when research published after the briefing showed measurable declines in acetaminophen use among pregnant patients, including in emergency settings.
If you are pregnant and worried, that worry deserves a real answer, not a dismissal. Bring it to your obstetrician and make the decision together, based on your situation.
Why "no drug treats autism" is still the accurate summary
As of today, no medication is approved to treat the core features of autism, meaning differences in social communication and restricted or repetitive patterns of behavior. Medications can play an important role in supporting autistic children with co-occurring conditions such as ADHD, anxiety, seizure disorders, or sleep difficulties, always under medical supervision.
The interventions with the strongest evidence base for building communication, adaptive skills, and independence remain behavioral and developmental approaches, individualized to the child and started as early as possible. That is not a promise of any specific outcome, and any provider who guarantees one should be treated with caution. It is a statement about where decades of peer-reviewed evidence currently point.
How to bring this to your pediatrician
Bring the specific claim you saw, not a general worry. "I read that leucovorin helps speech, does anything about my child's history make that worth evaluating?" is a question a pediatrician can actually work with.
Ask what testing would even establish. Cerebral folate deficiency is rare and has its own diagnostic pathway; whether any evaluation makes sense for your child is exactly the kind of individualized judgment your pediatrician is for.
Do not start or stop any medication, for your child or during pregnancy, based on a press conference, a headline, or a social media post. And ask your clinician for the AAP and SDBP family materials; the SDBP family statement is available in Spanish, which matters for many of the families we serve.
If you are earlier in the journey and still working through evaluation, our guides on navigating an autism diagnosis and the diagnosis gap in Hispanic communities walk through those steps.
The bottom line for families
Leucovorin has preliminary evidence for some symptoms in some children, an FDA label action tied to a rare condition rather than to autism broadly, and no routine-use recommendation from the AAP. Acetaminophen in pregnancy remains recommended when needed, and the strongest available research does not support the claim that it causes autism. No medication treats the core features of autism, and the evidence-based path for building skills runs through individualized behavioral and developmental intervention plus good medical care for co-occurring conditions.
The federal confirmatory trials on leucovorin will report in the coming years, and real evidence deserves a real update. When those results publish, we will revise this article. Until then, the best move is the same one it was before the press conference: a calm, specific conversation with your child's pediatrician.
